This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Chong Kun Dang Pharmaceutical Corporation. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Seongae Yoon: Innovator in Histone Deacetylase Inhibitors
Introduction
Seongae Yoon is a prominent inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of selective histone deacetylase inhibitors. His work is crucial for advancing treatments for various diseases.
Latest Patents
Yoon holds a patent for "Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same." This patent includes urea derivatives of Formula I, which exhibit histone deacetylase (HDAC) inhibitory activity. The optical isomers and pharmaceutically acceptable salts of these derivatives are also covered in the patent. These compounds are effective in treating histone deacetylase-mediated diseases, including malignant tumors, inflammatory diseases, rheumatoid arthritis, and neurodegeneration.
Career Highlights
Seongae Yoon is associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to innovate in the pharmaceutical sector. His research and development efforts have positioned him as a key figure in the industry.
Collaborations
Yoon collaborates with notable colleagues, including ChangSik Lee and Soyoung Kim, to further enhance the impact of his research.
Conclusion
Seongae Yoon's contributions to the field of histone deacetylase inhibitors represent a significant advancement in pharmaceutical science. His work holds promise for the treatment of serious medical conditions, showcasing the importance of innovation in healthcare.